Evidence map›Paper›PMID 41039689›Full record

ArticleMolecular pharmacology2025

Cholesterol residence time drives regulation of the G protein-coupled cholecystokinin receptor.

Chirine Toufaily, Yuanyuan Ma, Emmanuel D Barbosa, Kaleeckal G Harikumar, Denise Wootten, Patrick M Sexton, Wei Liu, Laurence J Miller

Abstract read
In one paragraph

Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chirine ToufailyDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona.
Yuanyuan MaCancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Emmanuel D BarbosaCancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Kaleeckal G HarikumarDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona.
Denise WoottenDrug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; ARC Centre for Cryo-electron Microscopy, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Patrick M SextonDrug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; ARC Centre for Cryo-electron Microscopy, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Wei LiuCancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: weiliu@mcw.edu.
Laurence J MillerDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona. Electronic address: miller@mayo.edu.

Funding

Impact of membrane composition on cholecystokinin receptor structure and functionR01GM141003 · NIGMS · MAYO CLINIC ARIZONA · PI MILLER, LAURENCE J · 2022 to 2025
$1.9M
Structural Biology of Dopamine SignalingR01GM140078 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI LIU, WEI · 2021 to 2024
$1.3M
NIGMS NIH HHS R01 GM140078NIGMS NIH HHS R01 GM141003
6 · The paper itself

Abstract

Membrane cholesterol modulates the ability of cholecystokinin to act at the type 1 cholecystokinin receptor (CCK1R), with elevated levels of this lipid that can be present in obesity, disrupting stimulus-activity coupling. This occurs via direct effect on a cholesterol association (cholesterol recognition/interaction amino acid consensus) motif within CCK1R, whereas an analogous motif is present in the type 2 cholecystokinin receptor (CCK2R) with no functional impact of cholesterol on that receptor. We recently demonstrated that surface residues surrounding this motif in these 2 G protein-coupled receptors could be exchanged as a group to convert their cholesterol sensitivity. We now evaluate each of these residues individually and use molecular dynamics to study cholesterol interactions with this site. These studies show that cholesterol occupies this motif in both CCK1R and CCK2R with similar dominant poses in both receptors in normal, as well as in elevated cholesterol environments. The dominant pose of cholesterol changes in both receptors with elevated cholesterol, shifting proximity from transmembrane segment (TM) 3 toward transmembrane segment 5. Of note, cholesterol residence time at this motif is longer for CCK2R than CCK1R and longer in high cholesterol conditions at both receptors. This suggests that the cholesterol sensitivity of CCK1R is likely a dynamic event mediated by short, transient cholesterol interaction with CCK1R under normal conditions. One residue in position 5.52 was critical for this cholesterol effect on CCK1R, despite the prediction that this is not due to direct interaction with cholesterol. Instead, the packing of hydrophobic residues around 5.52 is tighter in CCK1R than in CCK2R, likely affecting the position and movement of transmembrane segment 5 that are important for stimulus-activity coupling. SIGNIFICANCE STATEMENT: Membrane cholesterol can affect the function of select G protein-coupled receptors, such as the type 1 cholecystokinin receptor, that are targets for drugs in disease states in which membrane cholesterol can be elevated. This article studied the molecular basis for high cholesterol disruption of stimulus-activity coupling at this receptor using site-directed mutagenesis and molecular dynamics. The findings demonstrate that cholesterol residence time at a key cholesterol association motif within CCK1R is responsible for this effect.

Indexed as

CholesterolReceptor, Cholecystokinin AReceptor, Cholecystokinin BReceptors, CholecystokininAmino Acid MotifsAnimalsCholecystokininHEK293 CellsHumansMolecular Dynamics SimulationCholecystokininCholesterolReceptor, Cholecystokinin AReceptor, Cholecystokinin BReceptors, CholecystokininCholecystokininCholesterolG protein-coupled receptorMolecular dynamicsObesity

Identifiers

PMID41039689
PMCPMC13168989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.